Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Aims: To establish an automated method for identifying referable diabetic retinopathy (DR), defined as moderate nonproliferative DR and above, using deep learning-based lesion detection and stage grading.

Materials And Methods: A set of 12,252 eligible fundus images of diabetic patients were manually annotated by 45 licenced ophthalmologists and were randomly split into training, validation, and internal test sets (ratio of 7:1:2). Another set of 565 eligible consecutive clinical fundus images was established as an external test set. For automated referable DR identification, four deep learning models were programmed based on whether two factors were included: DR-related lesions and DR stages. Sensitivity, specificity and the area under the receiver operating characteristic curve (AUC) were reported for referable DR identification, while precision and recall were reported for lesion detection.

Results: Adding lesion information to the five-stage grading model improved the AUC (0.943 vs. 0.938), sensitivity (90.6% vs. 90.5%) and specificity (80.7% vs. 78.5%) of the model for identifying referable DR in the internal test set. Adding stage information to the lesion-based model increased the AUC (0.943 vs. 0.936) and sensitivity (90.6% vs. 76.7%) of the model for identifying referable DR in the internal test set. Similar trends were also seen in the external test set. DR lesion types with high precision results were preretinal haemorrhage, hard exudate, vitreous haemorrhage, neovascularisation, cotton wool spots and fibrous proliferation.

Conclusions: The herein described automated model employed DR lesions and stage information to identify referable DR and displayed better diagnostic value than models built without this information.

Download full-text PDF

Source
http://dx.doi.org/10.1002/dmrr.3445DOI Listing

Publication Analysis

Top Keywords

test set
16
identifying referable
12
internal test
12
deep learning-based
8
detection stage
8
diabetic retinopathy
8
fundus images
8
external test
8
referable identification
8
auc 0943
8

Similar Publications

Preclinical stroke research faces a critical translational gap, with animal studies failing to reliably predict clinical efficacy. To address this, the field is moving toward rigorous, multicenter preclinical randomized controlled trials (mpRCTs) that mimic phase 3 clinical trials in several key components. This collective statement, derived from experts involved in mpRCTs, outlines considerations for designing and executing such trials.

View Article and Find Full Text PDF

In recent AI-driven disease diagnosis, the success of models has depended mainly on extensive data sets and advanced algorithms. However, creating traditional data sets for rare or emerging diseases presents significant challenges. To address this issue, this study introduces a direct-self-attention Wasserstein generative adversarial network (DSAWGAN) designed to improve diagnostic capabilities in infectious diseases with limited data availability.

View Article and Find Full Text PDF

This study aims to investigate the predictive value of combined phenotypic age and phenotypic age acceleration (PhenoAgeAccel) for benign prostatic hyperplasia (BPH) and develop a machine learning-based risk prediction model to inform precision prevention and clinical management strategies. The study analyzed data from 784 male participants in the US National Health and Nutrition Examination Survey (NHANES, 2001-2008). Phenotypic age was derived from chronological age and nine serum biomarkers.

View Article and Find Full Text PDF

Purpose: Targeted therapy with lenvatinib is a preferred option for advanced hepatocellular carcinoma, however, predicting its efficacy remains challenging. This study aimed to build a nomogram integrating clinicoradiological indicators and radiomics features to predict the response to lenvatinib in patients with hepatocellular carcinoma.

Methods: This study included 211 patients with hepatocellular carcinoma from two centers, who were allocated into the training (107 patients), internal test (46 patients) and external test set(58 patients).

View Article and Find Full Text PDF

Introduction: Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objective response rates compared with tyrosine kinase inhibitor sorafenib; however, a majority of patients will still not respond to A/B. Strong scientific rationale and emerging clinical data suggest that faecal microbiota transfer (FMT) may improve antitumour immune response on PD-(L)1 blockade.

View Article and Find Full Text PDF